Managed Healthcare Executive January 31, 2025
The majority are in the very early preclinical stage of development, but applications for regulatory approval have been submitted for 11 gene therapies worldwide, and 35 are in phase 3 trials, according to report delineating the gene therapy development landscape.
Just over 2,000 gene therapies are at some stage of development and 11 are in the preregistration phase when the clinicals trials and the drug development companies have filed for regulatory approval, according to a report issued earlier this week by the American Society of Gene and Cell Therapy and Citeline, a pharma business intelligence company.
Six of the 11 gene therapies in preregistration are U.S. therapies, according to the 54-page report, which also reviews the development and business prospects...
Today's Sponsors
Today's Sponsor